Search

Your search keyword '"Stegmayr, B."' showing total 869 results
Start Over Author "Stegmayr, B."
869 results on '"Stegmayr, B."'

3. POS0214 IN-DEPTH ANALYSIS OF DISEASE MANIFESTATIONS IN ANCA-ASSOCIATED VASCULITIDES IDENTIFIES DISTINCT CLINICAL PHENOTYPES, EMPHASIZING THE IMPACT OF SEX AND AGE AT DIAGNOSIS

Author

Lindberg, H., primary, Rantapää Dahlqvist, S., additional, Norling, O., additional, Hellbacher, E., additional, Berglin, E., additional, Stegmayr, B., additional, Baslund, B., additional, Palm, Ø., additional, Haukeland, H., additional, Gunnarsson, I., additional, Bruchfeld, A., additional, Segelmark, M., additional, Olsson, S., additional, Mohammad, A. J., additional, Svärd, A., additional, Pullerits, R., additional, Herlitz, H., additional, Soderbergh, A., additional, Eriksson, P., additional, Knight, A., additional, and Dahlqvist, J., additional

Published
2023
Full Text
View/download PDF

5. The influence of body mass index on the accumulation of advanced glycation end products in hemodialysis patients

Author

Arsov, S., Trajceska, L., van Oeveren, W., Smit, A.J., Dzekova, P., Stegmayr, B., Sikole, A., Rakhorst, G., and Graaff, R.

Subjects
Advanced glycation end products -- Physiological aspects, Hemodialysis patients -- Physiological aspects -- Patient outcomes, Body mass index -- Measurement, Food/cooking/nutrition, Health
Abstract

BACKGROUND/OBJECTIVES: The level of skin autofluorescence (AF) at a given moment is an independent predictor of mortality in hemodialysis (HD) patients. Skin AF is a measure of the accumulation of advanced glycation end products (AGEs). The aim of the study was to estimate the influence of nutrition on the 1-year increase of skin AF (ΔAF) in HD patients. SUBJECTS/METHODS: A total of 156 HD patients were enrolled in this study. Skin AF, body mass index (BMI), superoxide dismutase, myeloperoxidase, C-reactive protein, inter-cellular adhesion molecule-1, von Willebrand factor and heart- type fatty acid-binding protein were measured four times at intervals of approximately half a year. Data from the monthly routine blood analysis were also used. Daily calorie, protein and AGE intakes were assessed from food recordings over a period of 1 week. RESULTS: A J-shaped relation was found between baseline BMI and ΔAF (P = 0.01). The lowest point of the J-shaped curve is found for BMI = 24.3 kg/[m.sup.2]. In the univariate analysis of the contributors to the 1-year ΔAF, we found that beside BMI = 24.3 kg/[m.sup.2], AGE and calorie intakes, as well as myeloperoxidase and HD vintage, had a P < 0.10. The sole independent predictor of the 1-year ΔAF was BMI = 24.3 kg/[m.sup.2] (P = 0.01). CONCLUSIONS: It appears that calorie, protein and AGE intakes hardly influence the 1-year ΔAF in HD patients. BMI of HD patients of around 24 kg/[m.sup.2] resulted in a lower 1-year ΔAF. European Journal of Clinical Nutrition (2015) 69, 309-313; doi: 10.1038/ejcn.2014.261; published online 14 January 2015, INTRODUCTION Advanced glycation end products (AGEs) are a result of nonenzymatic glycoxidative reactions also known as Maillard reactions, which may occur within the body (oxidative stress) or externally (food). AGE [...]

Published
2015
Full Text
View/download PDF

8. Thrombotic microangiopathy

Author

Mörtzell, M., Berlin, G., Nilsson, T., Axelsson, C.G., Efvergren, M., Audzijoni, J., Griskevicius, A., Ptak, J., Blaha, M., Tomsova, H., Liumbruno, G.M., Centoni, P., Newman, E., Eloot, S., Dhondt, A., Tomaz, J., Witt, V., Rock, G., and Stegmayr, B.

Published
2011
Full Text
View/download PDF

9. The contribution of educational class in improving accuracy of cardiovascular risk prediction across European regions: The MORGAM Project Cohort Component

Author

Ferrario, Marco M, Veronesi, Giovanni, Chambless, Lloyd E, Tunstall-Pedoe, Hugh, Kuulasmaa, Kari, Salomaa, Veikko, Borglykke, Anders, Hart, Nigel, Söderberg, Stefan, Cesana, Giancarlo, Jørgensen, T., Agger, C., Borglykke, A., Salomaa, V., Juolevi, A., Vartiainen, E., Jousilahti, P., Kuulasmaa, K., Cepaitis, Z., Haukijärvi, A., Joseph, B.J, Kulathinal, S., Niemelä, M., Saarela, O., Ducimetière, P., Bingham, A., Arveiler, D., Haas, B., Wagner, A., Ferrières, J., Ruidavets, J-B., Bongard, V., Amouyel, P., Montaye, M., Dallongeville, J., Döring, A., Wichmann, E., Ferrario, M., Ferrario, M., Veronesi, G., Cesana, G., Fornari, C., Sega, R., Mancia, G., Facchetti, R., Vanuzzo, D., Pilotto, L., Picco, F., Mattiussi, F., Gigante, S., Tamosiunas, A., Domarkiene, S., Rastenyte, D., Bernotiene, G., Radisauskas, R., Baceviciene, M., Luksiene, D., Malinauskiene, V., Bernotaite, L., Pająk, A., Kawalec, E., Broda, G., Kurjata, P., Rywik, S.L., Polakowska, M., Pytlak, A., Nikitin, Yu., Malyutina, S., Gafarov, V., Feigin, V., Siminova, G., Voevoda, M., Vinogradova, T., Nasonova, N., Veriovkin, E., Eliasson, M., Söderberg, S., Stegmayr, B., Eriksson, M., Asplund, K., Kee, F, Evans, A., Yarnell, J., Gardner, E., Tunstall-Pedoe, H., Woodward, M, Evans, A., Cashman, S., Evans, A., Blankenberg, S., Ferrario, M., Kee, F., Kuulasmaa, K., Palotie, A., Perola, M., Peters, A., Salomaa, V., Tregouet, D., Tunstall-Pedoe, H., Asplund, K., Cambien, F., Tiret, L, Peltonen, L., Shields, D., Stegmayr, B., and Wiklund, P.-G.

Published
2014
Full Text
View/download PDF

12. Analyses of registry data of patients with anti-GBM and antineutrophil cytoplasmatic antibody-associated (ANCA) vasculitis treated with or without therapeutic apheresis

Author

Henriksson, M. Mörtzell, Weiner, M., Sperker, W., Berlin, G., Segelmark, M., Martinez, A. Javier, Audzijoniene, J., Griskevicius, A., Newman, E., Blaha, M., Vrielink, H., Witt, V, Stegmayr, B., Henriksson, M. Mörtzell, Weiner, M., Sperker, W., Berlin, G., Segelmark, M., Martinez, A. Javier, Audzijoniene, J., Griskevicius, A., Newman, E., Blaha, M., Vrielink, H., Witt, V, and Stegmayr, B.

Abstract

Therapeutic apheresis (TA) as a treatment for antibody-associated vasculitis (AAV) was questioned by the PEXIVAS although the MEPEX study favored TA. The aim of this study was to evaluate the efficacy of TA to improve renal function in patients consecutively included in the WAA-apheresis registry versus patients not treated with TA. Materials and methods: Included were 192 patients that suffered from anti-glomerular basement membrane disease (anti-GBM, n = 28) and antineutrophil cytoplasmic antibody-associated vasculitis of MPO or PR3 origin. Of these 119 had performed TA and the other 73 had not performed TA for theses diagnoses (CTRL). Results: Elderly had an increased risk to die within 12 months (p = 0.002). All 28 anti-GBM had renal involvement, 21 dialysis dependent. At 3 month nine (36 %) did not need dialysis. Baseline data regarding renal function of AAV patients, subtype MPO and PR3, were worse in the TA groups than in CTRL. Recovery out of dialysis was better for the PR3-TA group compared with 1) the controls of MEPEX (RR 0.59, CI 0.43-0.80) and 2) the MPO-TA patients (RR 0.28, CI 0.12-0.68). The MPO-TA recovered similarly as the MEPEX-CTRL. Renal function improved most for TA-patients from baseline during the first 3 months (MPO-TA and PR3-TA) and stabilized thereafter and less for MPO-CTRL and PR3-CTRL. Conclusion: PR3-TA patients seem to have best chances to get out of dialysis. PR3-TA and MPO-TA improved residual renal function better than CTRL. The present study recommends reconsiderations to use TA for AAV especially those with PR3-vasculitis with severe renal vasculitis.

Published
2021
Full Text
View/download PDF

13. World apheresis registry 2003–2007 data

Author

Stegmayr, B., Ptak, J., Wikström, B., Berlin, G., Axelsson, C.G., Griskevicius, A., Centoni, P., Liumbruno, G., Molfettini, P., Audzijoniene, J., Mokvist, K., Sojka, B. Nilsson, Norda, R., Knutson, F., Ramlow, W., Blaha, M., Witt, V., Evergren, M., and Tomaz, J.

Published
2008
Full Text
View/download PDF

17. Stroke unit care revisited: who benefits the most? A cohort study of 105 043 patients in Riks-Stroke, the Swedish Stroke Register

Author

Terent, A., Asplund, K., Farahmand, B., Henriksson, K.M., Norrving, B., Stegmayr, B., Wester, P.-O., Asberg, K.H., and Asberg, S.

Subjects
Stroke (Disease) -- Care and treatment, Stroke (Disease) -- Patient outcomes, Hospitals -- Sweden, Hospitals -- Services, Death -- Prevention, Death -- Risk factors, Patients -- Care and treatment, Patients -- Research, Health, Psychology and mental health
Published
2009

24. PANORAMA OF ADVERSE EVENTS DURING CYTAPHERESIS: O127 (S.4-5)

Author

Stegmayr, B., Ptak, J., Nilsson, T., Berlin, G., Mirea, V., Axelsson, C. G., Griskevicius, A., Centoni, P., Liumbruno, G., Audzijoniene, J., Mokvist, K., Lassen, E., Knutson, F., Norda, R., Mörtzel, M., Prophet, H., Ramlow, W., Blaha, M., Witt, V., Efvergren, M., Tomaz, J., Newman, E., Eloot, S., Dhondt, A., Lalic, K., Sikole, A., Derfler, K., Hrdlickova, R., Tomsova, H., Gasova, Z., Bhuiyan-Ludvikova, Z., Ramsauer, B., and Vrielink, H.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results